Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
about
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceEnterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosisPrediction of hepatic clearance in human from in vitro data for successful drug development.Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patientsDedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!Understanding and preventing drug-drug and drug-gene interactions.Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs.Quantitation of small intestinal permeability during normal human drug absorption.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Cyclosporin therapeutic drug monitoring--an established service revisited.Metabolic routes along digestive system of licorice: multicomponent sequential metabolism method in rat.Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in manCytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humansThe use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Intestinal permeability and its relevance for absorption and elimination.Population-based mechanistic prediction of oral drug absorptionOral cyclosporine A--the current picture of its liposomal and other delivery systems.Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.The drug transporter-metabolism alliance: uncovering and defining the interplay.The role of transporters in the pharmacokinetics of orally administered drugs.Human clearance prediction: shifting the paradigm.Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.The role of diet on the clinical pharmacology of oral antineoplastic agents.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Population pharmacokinetics of cyclosporine in transplant recipients.Loss of orally administered drugs in GI tract.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.Ciclosporin 10 years on: indications and efficacy.Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.Challenges Associated with Route of Administration in Neonatal Drug Delivery.BDDCS, the Rule of 5 and drugability.Development and validation of a HPLC method for the determination of cyclosporine a in new bioadhesive nanoparticles for oral administrationIntravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient.Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.Human jejunal effective permeability and its correlation with preclinical drug absorption models.Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
P2860
Q28204828-05E43635-CCEE-4A86-90CF-E34FD1A99E0DQ28367522-67A0C1A5-5FED-4BF5-9624-E63AC6190F56Q33437736-97AB02A2-7669-466F-BE49-896217CAC1E1Q33869988-0C7C76E2-D253-437A-B2FC-C9CAAB1D5D96Q34289184-AAF837DC-1EBD-4450-82C0-2BE9D1BD5208Q34415944-6659606A-8531-464A-8720-82B327285FF6Q34470793-8A1AA3C4-D35E-40C6-957B-4825CF55397CQ34783396-05A780D8-3AAD-47CA-92DE-491DB7476B3CQ35129048-039411C0-F65C-4E64-8F85-11AB608668EEQ35759193-22474639-DC46-4688-A944-FCF037A2EE3EQ35791645-9C99BCB9-0FB2-4BA8-90C3-8104262B68F5Q35803002-F7705489-B372-4D3E-ACB6-2394FC31BDA0Q35827133-6A6A2F99-903D-400C-8686-FC84D472A853Q35876954-896E3364-8B32-4624-9985-345A9851ED2CQ35980234-4F824FB0-E805-48C8-8264-4E03D60C4FC5Q36053628-0B947BA9-DE0B-437D-8916-599BFA468493Q36088451-E68B9204-E1CF-44FA-A505-B873517B4646Q36985043-C8E72D74-4EF8-4C62-80C8-9D18F4AE5CE7Q37214520-EDC4CA37-55F6-47F1-96BC-E8C6389066A6Q37324276-BEFB0B16-2FAD-4008-8725-8A5ECD17D3ADQ37367800-66D5565F-32CD-4911-9F56-6C40BCA27B0DQ37485904-6B13A6C8-46EA-415E-9473-995982D61724Q37537018-7C1AB5C8-2970-41E9-9358-D53071906306Q37554400-9FD75D84-5F69-4D8B-8EC0-8F7F4E17DFE2Q37650803-467BD68B-8555-42A3-A497-B223B3EDE89EQ37907103-C1249CD5-C49E-48E1-91FD-210CF7F62973Q38086777-02BB0D51-51A9-41C9-B50A-69FDF1BEA7B5Q38115174-466EBBFC-258C-4874-8992-F19D82DD4F53Q38130231-9A27DFFF-B94D-440A-9229-C5CC251CCBC2Q38131859-F9F72064-8B69-4B43-AB99-628F2DE3E218Q38200541-7A26CB13-4328-47FD-B30F-8E0697787B5FQ38306645-096C4664-8BD3-4A95-A46C-9DD5210653B7Q38340831-150AF752-CE89-4D0B-B4F6-E28D620C2115Q38561363-6FFDBAE3-80B7-4B32-BC24-0138F12B428AQ38835159-F7BE55E6-248A-42F8-BA92-DFAB0F800EA6Q39671883-280C7845-BE12-4018-92B9-3B3FE7849205Q40586549-688DE427-56A5-49F6-B0F9-8EDD6F03E96BQ41456111-041148E2-7A2C-41E5-B47E-4763CCB7B0E0Q41561820-FA35062E-F4FC-4505-BCC8-5E50AD5B532AQ41596616-A669B1DE-9A20-45D4-961A-6B5AF2D56F97
P2860
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Differentiation of absorption ...... ns: studies with cyclosporine.
@en
Differentiation of absorption ...... ns: studies with cyclosporine.
@nl
type
label
Differentiation of absorption ...... ns: studies with cyclosporine.
@en
Differentiation of absorption ...... ns: studies with cyclosporine.
@nl
prefLabel
Differentiation of absorption ...... ns: studies with cyclosporine.
@en
Differentiation of absorption ...... ns: studies with cyclosporine.
@nl
P2093
P1476
Differentiation of absorption ...... ns: studies with cyclosporine.
@en
P2093
P2860
P304
P356
10.1016/0009-9236(95)90168-X
P407
P577
1995-11-01T00:00:00Z